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2017 ANNUAL REPORT

Women & HIV Prevention:

EXPANDING
THE OPTIONS,
EMPOWERING
WOMEN

Dear friends and colleagues,
Each year, we take stock of progress in HIV prevention research and development. As with all types of product
development, the field has seen growth, victories and setbacks. Through it all, women have remained at the core
of IPM’s mission, given their urgent and unmet need for new prevention options.
Equipping women with the range of tools they need to protect their sexual and reproductive health is vital. We are
making strides with the first long-acting HIV prevention product, one that could give women more control in staying
HIV-free. In 2017, IPM submitted the first regulatory application for the monthly dapivirine ring, and earlier this year,
interim data from two open-label studies of the ring suggested encouraging increases in use and risk reduction.

Dr. Zeda F. Rosenberg
Founder and CEO

These milestones toward the ring’s potential introduction were possible only through the steadfast and determined
efforts of our donors and many partners, and, most important, the women participating in the ring studies. We are
proud to work with so many individuals and institutions dedicated to realizing a future where women have choices to
stay healthy on their own terms. This shared commitment is essential to making the ring available, if it is approved.
Women’s sexual and reproductive health needs are multiple and varied, and their product options should be, too.
IPM is prioritizing the development of next-generation microbicides that would expand the spectrum of women’s
long-acting prevention technologies: a three-month dapivirine-only ring and a three-month dapivirine-contraceptive
ring that both entered safety clinical trials in 2017.
We know that products alone cannot change the course of an epidemic as complex as HIV/AIDS. Gender dynamics,
cultural norms and socioeconomic factors are significant determinants of risk. Yet without a wider set of prevention
tools, HIV will continue to threaten women’s lives.
When one woman first enrolled in the Phase III dapivirine ring trials, she discovered that she could use the product
discreetly and said, “That means I can use it without compromising.” Women should never have to compromise on
protecting their health. Together, we can empower women with more options so they won’t have to.

Dr. James McIntyre
Chair of the Board

Current prevention products are not doing enough for women. Every day, nearly 2,000
women, many of whom live in sub-Saharan Africa, become infected with HIV. Young
women ages 15-24 in the region are more than twice as likely to acquire HIV as young
men of the same age.
When HIV/AIDS threatens women’s health, the well-being of their families and
communities also suffer. But when women can protect their sexual and reproductive
health, they can better care for their families, tap into educational and economic
opportunities for themselves and their children, and pursue their dreams.
That is why IPM remains committed to developing woman-centered
technologies that would expand women’s prevention options and
allow them to stay healthy on their own terms:

BECAUSE

> women should be able to choose a method that meets their needs.
> women deserve the chance to live without fear of HIV.
> healthy women are empowered women.
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Woman-centered prevention:
Advancing the dapivirine ring
In 2016, a monthly vaginal ring containing the antiretroviral (ARV) drug dapivirine
was found to reduce women’s HIV risk in two Phase III clinical trials and to be
well-tolerated. Women inserted the flexible silicone ring themselves and left it in
place for a month. IPM developed the ring and is now leading public health and
regulatory efforts to potentially obtain approval for the ring’s use and roll out the

In 2017, IPM advanced research on three
microbicide vaginal rings designed to
offer women discreet, long-acting

product in countries where women face high HIV risk.

Strengthening the dapivirine ring evidence base
IPM and its partner, the US National Institutes of Health-funded Microbicide
Trials Network (MTN), launched two open-label extension studies in 2016, called

prevention. Take a look at how these

DREAM and HOPE, to provide the active ring for one year to former Phase III

innovative tools are progressing.

product adherence and collecting additional safety data.

participants. The IPM-led DREAM and MTN-led HOPE studies are also assessing

In February 2018, IPM and MTN presented interim results for the DREAM and
HOPE open-label studies at the Conference on Retroviruses and Opportunistic
Infections (CROI) in Boston. As of late 2017:
• Adherence had increased from approximately 80 percent across the Phase III
trials to approximately 90 percent across both open-label studies.
• Data suggest that women’s HIV risk is being reduced by approximately half
in DREAM and HOPE compared to 30 percent in the Phase IIIs. (Because
open-label studies do not have placebo groups for comparison, risk reduction
was estimated using mathematical modeling.)
• The ring has been well-tolerated in the open-label studies.

2 IPM 2017 ANNUAL REPORT

Although the data have limitations, they suggest that when women know the
ring reduced HIV risk in large clinical trials, they are more likely to use the
product and see greater protection. These encouraging results are similar to the
results of early open-label studies of oral pre-exposure prophylaxis, or PrEP, a
daily pill to prevent HIV, which showed steady increases in adherence and HIV
risk reduction compared to Phase III studies. PrEP has since been approved for
use and implementation studies and market introduction efforts are under way
across sub-Saharan Africa.
It is hoped that the improving adherence and risk reduction trends will continue
for the ring as it did in open-label studies of PrEP. DREAM and HOPE will
conclude at the end of 2018, with final results expected in 2019.

IPM’s clinical research center partners, including the Desmond Tutu HIV Foundation in Masiphumelele, South Africa, are
conducting an open-label study of the dapivirine ring to learn how the ring could fit into women’s lives.

A staff member at the MatCH research center in
Edendale, South Africa, demonstrates how to insert
a vaginal ring at a journalist training on women’s HIV
prevention and microbicides.
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Ring Use Among Young Women: The dapivirine ring is early on the
path to potential introduction, and there is still more to learn about its safety and
use, including among adolescent girls and young women. A joint IPM/MTN study
among adolescent girls ages 15-17 in the US presented at the 2017 International
AIDS Society Conference on HIV Science (IAS 2017) showed that the ring was
well-tolerated, and the majority of girls liked the ring and found it easy to use.
In addition, MTN, in partnership with IPM, plans to initiate the REACH study in
early 2019 to assess adherence to and preferences for the monthly dapivirine ring
and daily oral PrEP among adolescent girls and young
women in eastern and southern Africa. REACH will also look
at the safety of both products in this high-risk population.
MTN and AVAC, in collaboration with IPM, met with young women, civil society,
government representatives, researchers and advocates to gather feedback on the
REACH study planned for early 2019 (Courtesy of MTN).

Finding Solutions for New and Expecting Mothers:
Recent research suggests that women’s HIV risk is three times
higher than normal during pregnancy and four times higher in the
six months following birth, when some women are breastfeeding.
Yet little research exists on the safety of HIV prevention products
during these periods. IPM’s clinical program for the dapivirine
ring aims to address this knowledge gap.

Ring Safety in Pregnant and Breastfeeding Women: Results of an
IPM/MTN safety study among lactating women in the US, also presented at IAS
2017, found the ring to be well-tolerated, with low dapivirine levels in mothers’

“

I don’t want to see any women getting HIV.
If anyone is excited about the ring, it’s me.”
– Margaret Happy, SRHR advocate
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breast milk and blood plasma, and low estimated drug uptake in infants. Based
on those encouraging results, IPM and MTN are now planning safety studies
among pregnant and breastfeeding women in four countries in Africa, expected
to begin in 2019.

Pursuing regulatory approval for the dapivirine ring
Given women’s urgent need for discreet, self-initiated HIV prevention options
and the dapivirine ring’s potential public health impact, IPM is pursuing
regulatory approvals for the ring in countries in sub-Saharan Africa with high
incidence rates among women.
In June 2017, IPM submitted a regulatory application to the European Medicines
Agency (EMA) for the monthly ring under a procedure known as Article 58. That
procedure assesses the quality, safety and efficacy of a medicine for high-priority
diseases and provides a scientific opinion on the benefit-risk ratio for a
medicine’s use in low-income countries outside of the European Union,
in cooperation with the World Health Organization (WHO).

Dapivirine ring application: By-the-numbers
The EMA submission was the culmination of
intensive work assembling a comprehensive
dossier of data on both the ring and
dapivirine, a new chemical entity that has
not undergone previous regulatory review.

250
260,000
1st

studies incorporated
pages in electronic submission
regulatory application for a microbicide

A positive opinion from the EMA would facilitate a decision by the WHO on the
ring’s prequalification, a designation that many national regulatory authorities in
Africa use to determine their own product approvals.
IPM’s next regulatory steps include plans to submit applications to the South African
Health Products Regulatory Authority in 2018, followed by the US Food and Drug
Administration and other African regulators.
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Access partnerships for potential ring introduction

In addition, IPM convened 12 experts

Maximizing the ring’s potential public health impact means ensuring its cost-effec-

September 2017 for the first meet-

tiveness to country governments, and its affordability and availability to women.

ing of the Dapivirine Ring Access

IPM is working with partners across multiple sectors to share resources and learn

Advisory Committee. The multidisci-

from market introduction efforts of other HIV prevention and biomedical products.

plinary group is drawing on extensive

IPM continues to deepen its partnership with Johnson & Johnson (J&J), which

product access experience in Africa

granted IPM exclusive worldwide rights to dapivirine in 2014 through Janssen

to help ensure the ring’s successful

Sciences Ireland UC. This landmark agreement builds on the original royalty-free

introduction where it is most urgently

license IPM received from Janssen in 2004 to develop dapivirine as a microbicide.

needed, if it is approved.

With the assistance of J&J product access experts, IPM refined its ring access
strategy in 2017 and planned market research studies to inform future policy and
education initiatives.

from different countries and sectors in

2017 Dapivirine Ring Access Advisory Committee Members
Georgina Caswell, MA, Chair
International HIV/AIDS Alliance, South Africa

Bob Mwiinga Munyati, MPH
AIDS Accountability International, South Africa

Diana Amanyire, MPH
Marie Stopes International, Uganda

Brian Ngwira, MBBS
Family Planning Association of Malawi, Malawi

Brenda Facy Azizuyo
International Community of Women Living with HIV,
Uganda

Lebogang Ramafoko, MC/MPA
Soul City Institute, South Africa

Manju Chatani, MPH
AVAC, United States
Frances Cowan, MD, MS, MBBS
Liverpool School of Tropical Medicine and Centre for
Sexual Health and HIV/AIDS Research, Zimbabwe
Maximina Jokonya
Africaid, Zimbabwe

USAID’s Center for Accelerating Innovation and Impact
worked with IPM to gather insights from young women
that could inform the ring’s potential rollout.
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“

Jens Van Roey, MD
Independent Consultant, Belgium
Daniel Were, PhD, MA
Jhpiego, Kenya
Samantha Willan, MA
What Works to Prevent Violence Against Women
and Girls Programme, South Africa

We must all join forces to support the world’s
young women.”

– Jaak Peeters, global head, Global Public Health, Johnson & Johnson

Advancing next-generation
microbicides
IPM’s efforts to expand women’s prevention options do not stop with the monthly
DAPIVIRINE RING
THE CASE FOR ACTION

RESEARCH BY

dapivirine ring. Women have different needs that change and intersect throughout
their lives. Using the monthly ring as a platform, IPM is prioritizing the development of
next-generation vaginal rings that could offer women greater convenience and versatility.

IPM is also partnering with the OPTIONS project, part of the USAID-funded

A three-month dapivirine ring entered a first Phase I trial in 2017 to assess the ring’s

Microbicide Product Introduction Initiative. In consultation with IPM,

safety and pharmacokinetics among women in the US, with results expected in early

OPTIONS developed an investment case for the ring in 2017 to inform

2019. This longer-acting ring would help reduce costs and minimize women’s visits to a

public health decision-making. IPM also worked with USAID’s Center

health facility to obtain the product.

for Accelerating Innovation and Impact, which in 2017 published a
human-centered design guide to encourage ring uptake and consistent
use, especially among young women in sub-Saharan Africa. The guide
includes insights and tools that can be adapted to design educational
outreach and marketing strategies customized to the needs of different
groups and contexts.
Ngoba bathi AIDS ayilapheki,
soyinqoba ngeringi namhlanje yemicrobicides
Because they say AIDS is not treatable,
we will defeat it with microbicide ring

Many women have expressed interest in a method that would give them long-acting
control over HIV prevention and contraception in a single product. IPM’s three-month
dapivirine-contraceptive ring also entered a first Phase I trial in 2017, final results of which
are expected in 2018. Given encouraging preliminary data, a second Phase I trial began
in 2018. A multipurpose ring could have an important impact on the sexual and
reproductive health for many of the 214 million women in developing countries who
want but lack access to a modern family planning method, many of whom are also at
high risk of HIV infection.
Pending study results and the potential rollout of the monthly dapivirine ring, IPM will
determine the path forward for these longer-acting next-generation rings.

– Song excerpt from DREAM study communities, in Zulu and English
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Empowering women
through HIV prevention:
Advancing the conversation
Broadening the range of women’s sexual and reproductive health tools would not
only support the United Nations’ target to reduce new adult HIV infections by 90 percent, but also give women more opportunities to thrive, and contribute to the growth
of their communities and societies. IPM is raising awareness about the connections
between reducing HIV infections among women and global development among
scientific, policymaking and general audiences alike—because everyone has a role to
play in empowering women to stay healthy.
The intersections between women’s empowerment, gender equality and health
were featured in discussions at the 61st Commission on the Status of Women in
New York, where IPM organized an event highlighting how innovative HIV prevention
technologies could advance young women’s economic empowerment. Co-hosted
by AVAC, USAID’s Center for Accelerating Innovation and Impact, and Dalberg’s

IPM and its global partners were recognized at the Innovation for Impact Awards for their pioneering work to develop
the dapivirine vaginal ring.

Design Impact Group, attendees discussed how human-centered design could
contribute to the successful introduction of HIV prevention technologies such as PrEP
and the dapivirine ring, if it is approved, among young women and adolescent girls.

IPM and the Population Council partnered in November 2017 to hold the first in

IPM also organized a satellite session at the Southern African AIDS Conference

reproductive health. From multipurpose prevention to long-acting contraception,

in June 2017 to provide updates on dapivirine ring research and foster discussion
on HIV prevention product adherence among women and product options. IPM
continued to spread the word about ring results and next steps throughout the year
at outreach events such as youth and community awareness events in Africa and
meetings with advocates, civil society organizations and governments in the US,
Canada and Europe.

a series of webinars exploring vaginal rings and their role in women’s sexual and
self-initiated vaginal rings could be important new tools for women.
IPM was honored to accept the Global Health Technologies Coalition’s inaugural
Innovation for Impact Partnership Award on behalf of the many partners that
helped us develop and research the dapivirine ring. At the December 2017 awards
ceremony, IPM joined representatives from Johnson & Johnson and USAID to discuss
how different sectors came together to advance this innovative technology, and the
need for continued collaboration to make the product available if it is approved.
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“

Dual-purpose rings like this one, which give women control
over their health in intersecting ways, are the leading edge
of contraceptive technology. Imagine a world where we don’t
have to choose between ‘good enough’ options for staying
healthy and planning our futures, because all our options are
designed with our needs in mind.”
– Shannon Davis, Knowledge for Health Project

IPM CEO Zeda Rosenberg met with Danish Parliament members at the UN High-Level Political Forum.

IPM held a variety of community
events, including these soccer and
netball tournaments, to continue
raising awareness about HIV.

At the UN’s Commission on the Status of Women, IPM event attendees discuss the links
between HIV prevention, product innovation and young women’s empowerment.
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IPM Donors
2017 Donors
Bill & Melinda Gates Foundation

Previous Donors
Ackerman Family Foundation
Belgian Development Cooperation
Canadian International Development Agency

Ministry of Foreign Affairs of Denmark

European Commission

Flanders Department of Foreign Affairs

Federal Ministry for Economic Cooperation and
Development, Germany

German Federal Ministry of Education and Research (BMBF)
through the KfW Development Bank
Irish Aid, Department of Foreign Affairs and Trade
Ministry of Foreign Affairs of the Netherlands through the
Netherlands Enterprise Agency
United Kingdom Department for International Development
United States Agency for International Development through
the United States President’s Emergency Plan for AIDS Relief

M•A•C AIDS Fund
Magee-Womens Research Institute and Foundation
Ministry for Foreign Affairs, Sweden
Ministry of Foreign Affairs and Cooperation, Spain
Ministry of Foreign Affairs, France
Norwegian Agency for Development Cooperation, Norwegian Ministry
of Foreign Affairs
OPEC Fund for International Development, the development finance
institution of OPEC Member States
Rockefeller Foundation
Swedish International Development Agency
United Nations Population Fund
World Bank
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2017 Board of Directors

2017 Scientific Advisory Boardd

James McIntyre, MBChB, Chair
Anova Health Institute, South Africa

Robin Shattock, PhD, Chair
Imperial College London, United Kingdom

Ayo Ajayi, MD, MPH
Independent Consultant, United States
Pamela W. Barnes, MBA
Independent Consultant, United States
Bruce Burlington, MD, Finance Committee member
Independent Consultant, United States
Alex Coutinho, MBChB, MPH, MSc, DTM&H
Partners in Health, Rwanda

David R. Friend, PhD
Daré Bioscience, United States
Sharon Hillier, PhD
Magee-Womens Hospital, University of Pittsburgh School of Medicine, United States
Ruth B. Merkatz, PhD, RN, FAAN
Population Council, United States
Thomas Moench, MD
ReProtect, Inc., United States
Beth Romach, PhD
ViiV Healthcare, United States

Florence Houn, MD, MPH
Celgene Corporation, United States

Doug Taylor, PhD
FHI 360, United States

Tamar Howson, MS, MBA, Finance Committee member
Independent Consultant, United States

Jim A. Turpin, PhD
National Institute of Allergy and Infectious Diseases, National Institutes of Health,
United States

Maureen Luba Milambe
Centre for the Development of People/Malawi Network of
People Living with HIV, Malawi
Lebogang Motsumi
HIV Activist, Coach and Speaker, South Africa
Ndola Prata, MD, MSc
University of California, Berkeley School of Public Health, United States
Zeda F. Rosenberg, ScD
IPM, United States
Michael Stevens, Finance Committee Chair
Independent Consultant, United Kingdom
Heidemarie Wieczorek-Zeul
Former Member of Parliament, German Bundestag, Germany

Lut Van Damme, PhD, MD
Bill & Melinda Gates Foundation, United States
Jens Van Roey, MD
Independent Consultant, Belgium

IPM Leadership
Zeda F. Rosenberg, ScD
Founder and Chief Executive Officer
Mike Goldrich, MBA
President and Chief Operating Officer
Brid Devlin, PhD
Executive Vice President, Product Development
Kathy Flynn, MBA
Chief Financial Officer
Patricia R. Mayer, PhD
Executive Vice President, Regulatory Affairs
Annalene Nel, MD, PhD
Executive Vice President, Chief Medical Officer, Clinical Programs
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2017 Financial Considerations
IPM’s cash, cash equivalents and short-term investments as of Dec. 31, 2017, totaled
USD 12 million. In 2017, IPM advanced three major programs:
•

“

Providing support to clinical research center partners and leading clinical
activities to conduct DREAM, an open-label extension study that launched in
July 2016 to provide the monthly dapivirine ring to former Ring Study participants and to learn more about how to support ring adherence. IPM also engaged
in chemistry, manufacturing and control activities to support the regulatory filing
to the EMA and prepare for the scale-up needed to introduce the ring, if it is
approved.

•

Conducting regulatory activities to seek approval for the dapivirine ring’s
use in African countries where women face high HIV risk. IPM submitted an
application to the EMA under Article 58 in June 2017, and currently plans to
submit applications to SAHPRA in late 2018, followed by the FDA in 2019.

•

Advancing next-generation products in IPM’s pipeline. In 2017, IPM initiated
the first clinical trial of a three-month dapivirine ring and the first clinical trial of a
three-month dapivirine-contraceptive ring. These innovative technologies would
expand women’s options for self-initiated, long-acting prevention.

Simply put, girls and women are the keys that will unlock
sustainable development. They are also at the center of the
healthier and more resilient societies we desire.

– Tedros Adhanom Ghebreyesus, director-general, World Health Organization
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In 2017, IPM received support from donors including the Ministry of Foreign Affairs of Denmark, the Flanders Department of Foreign Affairs, the German Federal
Ministry of Education and Research, Irish Aid, the Ministry of Foreign Affairs of the
Netherlands, DFID, USAID and the Bill & Melinda Gates Foundation. IPM received
approximately USD 37.2 million (cash receipts) in 2017.
IPM’s 2017 financial audits continue a history of full compliance with all financial
reporting requirements from all US and international government and private donors.
In 2017, IPM again received an unqualified, or clean, audit opinion across its South
Africa, US and Belgium offices.
IPM’s Board of Directors, management team and staff remain dedicated to efficiently
and effectively delivering on our mission to develop HIV prevention and other sexual
and reproductive health technologies for women, and to make them available and
accessible where they are urgently needed. Given the consistently high rates of new
HIV infections among women and girls, especially in sub-Saharan Africa, woman-centered technologies like the dapivirine ring could be a valuable addition to the suite of
HIV prevention options. Continued financial support for IPM’s work is essential
to capitalizing on the promise of microbicides for women’s health, and we
continue to advocate for increased funds from existing donors and to pursue new
funding sources.

2017 Expenditures By Activity
$36.8M
1%

3%

12%

Statement of Financial Position
December 31, 2017

Phase III and IIIb Trials (The Ring
Study and DREAM)
Chemistry, Manufacturing &
Controls

30%

Operations & Resource
Development

Regulatory

23%
15%

Product Pipeline

16%

Access
External Relations

Assets
Cash and cash equivalents
Investments, at fair value
Grants and accounts receivables
Prepaid expenditures and other assets
Property and equipment, net
Total assets

$11,761,856
247,161
6,653,755
692,463
3,694,037
$23,049,272

Liabilities and net assets
Liabilities
Accounts payable and accrued expenditures

2017 Expenditures by Functional Category
$36.8M
External Contracts
Personnel
Consulting Services
Other*
Travel

2%

2%

Deferred rent liability
Total liabilities

649,752
4,415,411
813,490
$9,788,866

Commitments and contingencies

9%
11%

Accrued payroll liabilities
Grant advances and deferred revenue

$3,910,213

Net assets:

42%

Without donor restrictions
Total liabilities and net assets

13,260,406
$23,049,272 		

33%

Depreciation

			
			

* Includes rent, internet/phone, clinical trial insurance, legal fees, audit fees, regulatory fees and miscellaneous.
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IPM Headquarters

IPM South Africa

IPM Belgium AISBL

www.IPMglobal.org

8405 Colesville Road
Suite 600
Silver Spring, MD 20910 USA
Tel: +1-301-608-2221
Fax: +1-301-608-2241

63 Main Road
Paarl 7646, South Africa
P.O. Box 3460
Tel: +27-21-860-2300
Fax: +27-21-860-3208/1000

Square de Meeûs 38/40
B1000 Brussels
Belgium

Follow us on Twitter
at @IPMicrobicides

